Details

Autor(en) / Beteiligte

• Li, Hao
• Zhang, Lei-Ke
• Li, Shu-Fen
• Zhang, Shao-Fei
• Wan, Wei-Wei
• Zhang, Yu-Lan
• Xin, Qi-Lin
• Dai, Ke
• Hu, Yuan-Yuan
• Wang, Zhi-Bo
• Zhu, Xiang-Tao
• Fang, Yu-Jie
• Cui, Ning
• Zhang, Pan-He
• Yuan, Chun
• Lu, Qing-Bin
• Bai, Jie-Ying
• Deng, Fei
• Xiao, Geng-Fu
• Liu, Wei
• Peng, Ke

Titel

Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality

Ist Teil von

• Cell research, 2019-09, Vol.29 (9), p.739-753

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2019

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Severe fever with thrombocytopenia syndrome (SFTS), an emerging tick-borne infectious disease caused by a novel phlebovirus (SFTS virus, SFTSV), was listed among the top 10 priority infectious diseases by the World Health Organization due to its high fatality of 12%-50% and possibility of pandemic transmission. Currently, effective anti-SFTSV intervention remains unavailable. Here, by screening a library of FDA-approved drugs, we found that benidipine hydrochloride, a calcium channel blocker (CCB), inhibited SFTSV replication in vitro. Benidipine hydrochloride was revealed to inhibit virus infection through impairing virus internalization and genome replication. Further experiments showed that a broad panel of CCBs, including nifedipine, inhibited SFTSV infection. The anti-SFTSV effect of these two CCBs was further analyzed in a humanized mouse model in which CCB treatment resulted in reduced viral load and decreased fatality rate. Importantly, by performing a retrospective clinical investigation on a large cohort of 2087 SFTS patients, we revealed that nifedipine administration enhanced virus clearance, improved clinical recovery, and remarkably reduced the case fatality rate by >5-fold. These findings are highly valuable for developing potential host-oriented therapeutics for SFTS and other lethal acute viral infections known to be inhibited by CCBs in vitro.